Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose + camrelizumab + rivoceranib first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2600134290Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2026
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acarbose, camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by First Hospital of China Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
acarbosecamrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600134290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134290.